EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

Addition of ruxolitinib and decitabine to modified busulfan/cyclophosphamide conditioning regimen for prophylaxis relapse in high-risk acute myeloid leukemia: the phase 2 prospective study

Yujun Wei, Kun Qian, Ning Le, Lili Wang, Fei Li, Songhua Luan, Lu Wang, Xiangshu Jin, Bo Peng, Nan Wang, Liping Dou, Daihong Liu

Annals of Hematology · 2024

DOI: 10.1007/s00277-024-05972-w ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Annals of Hematology, 2024. Verfasst von Yujun Wei und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Nankai University, Tianjin, 300071, China. Hauptthemen laut MEDLINE: Decitabine, Leukemia, Myeloid, Acute, Transplantation Conditioning, Busulfan. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Beijing Natural Science Foundation of China, Beijing Nova Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DecitabineLeukemia, Myeloid, AcuteTransplantation ConditioningBusulfanCyclophosphamidePyrimidinesPyrazolesAntineoplastic Combined Chemotherapy ProtocolsNitrilesHematopoietic Stem Cell TransplantationHumansAdultMaleFemaleMiddle AgedProspective StudiesAdolescentYoung AdultChildGraft vs Host DiseaseRecurrence

Stichwörter der Autor:innen

Acute myeloid leukemiaAllogeneic hematopoietic stem cell transplantationConditioning regimenRelapse

Substanzen

DecitabineBusulfanCyclophosphamidePyrimidinesPyrazolesNitrilesruxolitinib

Autor:innen und Institutionen

  • School of Medicine, Nankai University, Tianjin, 300071, China.
  • Chief Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100071, China.
  • Department of Hematology, The First Medical Center of Chinese PLA General Hospital, Beijing, 100853, China.
  • Chief Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100071, China. lipingruirui@163.com.
  • School of Medicine, Nankai University, Tianjin, 300071, China. daihongrm@163.com.
  • Chief Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100071, China. daihongrm@163.com.

Förderung

  • National Natural Science Foundation of China
  • Beijing Natural Science Foundation of China
  • Beijing Nova Program
  • National Key Research and Development Program of China
  • Military medical support innovation and generate special program
  • Special Research Found for Health Protection

Zitieren

APA

Wei, Y., Qian, K., Le, N., Wang, L., Li, F., Luan, S., Wang, L., Jin, X., Peng, B., Wang, N., Dou, L., & Liu, D. (2024). Addition of ruxolitinib and decitabine to modified busulfan/cyclophosphamide conditioning regimen for prophylaxis relapse in high-risk acute myeloid leukemia: the phase 2 prospective study. Annals of Hematology. https://doi.org/10.1007/s00277-024-05972-w

Vancouver

Wei Y, Qian K, Le N, Wang L, Li F, Luan S, et al. Addition of ruxolitinib and decitabine to modified busulfan/cyclophosphamide conditioning regimen for prophylaxis relapse in high-risk acute myeloid leukemia: the phase 2 prospective study. Annals of Hematology. 2024. doi:10.1007/s00277-024-05972-w

BibTeX
@article{Wei2024,
  author = {Wei, Yujun and Qian, Kun and Le, Ning and Wang, Lili and Li, Fei and Luan, Songhua and Wang, Lu and Jin, Xiangshu and Peng, Bo and Wang, Nan and Dou, Liping and Liu, Daihong},
  title = {Addition of ruxolitinib and decitabine to modified busulfan/cyclophosphamide conditioning regimen for prophylaxis relapse in high-risk acute myeloid leukemia: the phase 2 prospective study},
  journal = {Annals of Hematology},
  year = {2024},
  doi = {10.1007/s00277-024-05972-w}
}
Kostenlos starten →